Sanofi and AstraZeneca’s RSV antibody shows mettle in real-world results
Pharmaceutical Technology
MAY 15, 2023
Sanofi announced data from a real-world clinical trial that demonstrated its RSV antibody nirsevimab delivered an 83% reduction in hospitalisations in infants with respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). Nirsevimab is being jointly developed between Sanofi and AstraZeneca.
Let's personalize your content